279 related articles for article (PubMed ID: 15156500)
1. Multidrug-resistant HIV-1.
Tayloe D
Clin Infect Dis; 2004 May; 38(10):1507; author reply 1507. PubMed ID: 15156500
[No Abstract] [Full Text] [Related]
2. Changing transmission fitness of drug-resistant human immunodeficiency virus against a background of evolving antiretroviral therapy.
Murray JM
J Infect Dis; 2003 Oct; 188(8):1258; author reply 1258-9. PubMed ID: 14551898
[No Abstract] [Full Text] [Related]
3. Antiretroviral resistance.
Geretti AM
J HIV Ther; 2006 Dec; 11(4):72-3. PubMed ID: 17578209
[No Abstract] [Full Text] [Related]
4. HIV drug resistance and you. Resistance testing in experienced patients. Considerations when changing drugs.
Posit Aware; 2006; Spec No():17-22. PubMed ID: 16596730
[No Abstract] [Full Text] [Related]
5. The clinical significance of viral fitness.
Geretti AM
J HIV Ther; 2005 Mar; 10(1):6-10. PubMed ID: 15951728
[TBL] [Abstract][Full Text] [Related]
6. Detection and significance of minority quasispecies of drug-resistant HIV-1.
Metzner KJ
J HIV Ther; 2006 Dec; 11(4):74-81. PubMed ID: 17578210
[No Abstract] [Full Text] [Related]
7. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
8. Transmitted multidrug resistant HIV-1: new and investigational therapeutic approaches.
Shet A; Markowitz M
Curr Opin Investig Drugs; 2006 Aug; 7(8):709-20. PubMed ID: 16955682
[TBL] [Abstract][Full Text] [Related]
9. [Therapy of advanced stages. "Mega-HAART" or "drug holiday"?].
MMW Fortschr Med; 2000 Mar; 142 Suppl 1():86-7. PubMed ID: 10863323
[No Abstract] [Full Text] [Related]
10. Three-class-resistant human immunodeficiency virus type 1 variant in a drug-naive heterosexual couple.
Razzolini F; Saladini F; Malincarne L; Vicenti I; Palladino N; Romano L; Francisci D; Zazzi M
J Clin Microbiol; 2008 Nov; 46(11):3856-9. PubMed ID: 18845824
[TBL] [Abstract][Full Text] [Related]
11. Update of the drug resistance mutations in HIV-1: 2004.
Johnson VA; Brun-Vézinet F; Clotet B; Conway B; D'Aquila RT; Demeter LM; Kuritzkes DR; Pillay D; Schapiro JM; Telenti A; Richman DD
Top HIV Med; 2004; 12(4):119-24. PubMed ID: 15516709
[No Abstract] [Full Text] [Related]
12. Role of the inhibitory quotient in HIV therapy.
Hoefnagel JG; Koopmans PP; Burger DM; Schuurman R; Galama JM
Antivir Ther; 2005; 10(8):879-92. PubMed ID: 16430193
[TBL] [Abstract][Full Text] [Related]
13. Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network.
Chaix ML; Desquilbet L; Descamps D; Costagliola D; Deveau C; Galimand J; Goujard C; Signori-Schmuck A; Schneider V; Tamalet C; Pellegrin I; Wirden M; Masquelier B; Brun-Vezinet F; Rouzioux C; Meyer L; ;
Antivir Ther; 2007; 12(8):1305-10. PubMed ID: 18240870
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1.
de Mendoza C; Rodriguez C; Eiros JM; Colomina J; Garcia F; Leiva P; Torre-Cisneros J; Aguero J; Pedreira J; Viciana I; Corral A; del Romero J; Ortiz de Lejarazu R; Soriano V
Clin Infect Dis; 2005 Jul; 41(2):227-32. PubMed ID: 15983920
[TBL] [Abstract][Full Text] [Related]
15. New developments in HIV drug resistance.
Cane PA
J Antimicrob Chemother; 2009 Sep; 64 Suppl 1():i37-40. PubMed ID: 19675018
[TBL] [Abstract][Full Text] [Related]
16. [Highly active initial therapy without resistance development. Even after 6 years still effective HIV therapy].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():54-5. PubMed ID: 16385876
[No Abstract] [Full Text] [Related]
17. A single case of multidrug-resistant HIV and rapid disease progression.
O'Rourke M
AIDS Clin Care; 2005 Mar; 17(3):21-2. PubMed ID: 15828115
[No Abstract] [Full Text] [Related]
18. Revisiting the concept of a genetic barrier to resistance.
Rusconi S
J HIV Ther; 2006 Dec; 11(4):81-3. PubMed ID: 17578211
[No Abstract] [Full Text] [Related]
19. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
Ghosn J; Pellegrin I; Goujard C; Deveau C; Viard JP; Galimand J; Harzic M; Tamalet C; Meyer L; Rouzioux C; Chaix ML;
AIDS; 2006 Jan; 20(2):159-70. PubMed ID: 16511408
[TBL] [Abstract][Full Text] [Related]
20. Update of the drug resistance mutations in HIV-1: 2007.
Johnson VA; Brun-Vézinet F; Clotet B; Günthard HF; Kuritzkes DR; Pillay D; Schapiro JM; Richman DD
Top HIV Med; 2007; 15(4):119-25. PubMed ID: 17720996
[No Abstract] [Full Text] [Related]
[Next] [New Search]
